Prostate disorder
diseaseOn this page
Also known as disease of prostate glanddisease or disorder of prostate glanddisorder of prostate glandprostate diseaseprostate gland diseaseprostate gland disease or disorder
Summary
Prostate disorder (MONDO:0003105) is a disease (an umbrella term covering 5 Mondo subtypes) and 32 clinical trials. Top therapeutic interventions include alcohol, dalfampridine, and darolutamide. A subtype of male reproductive system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 5 Mondo subtypes
- Clinical trials: 32
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | prostate disorder |
| Mondo ID | MONDO:0003105 |
| EFO | EFO:0009602 |
| MeSH | D011469 |
| DOID | DOID:47 |
| NCIT | C26865 |
| SNOMED CT | 30281009 |
| UMLS | C0033575 |
| MedGen | 10964 |
| Anatomy (UBERON) | UBERON:0002367 |
| Is cancer (heuristic) | no |
Also known as: disease of prostate gland · disease or disorder of prostate gland · disorder of prostate gland · prostate disease · prostate disorder · prostate gland disease · prostate gland disease or disorder
Disease family
This is a subtype of male reproductive system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › male reproductive system disorder › prostate disorder
Related subtypes (25): benign male reproductive system neoplasm, hematocele of tunica vaginalis testis, male genital organ stricture, male genital organ vascular disease, penile disorder, testicular disorder, epididymitis, hydrocele, male infertility, male genital tuberculosis, spermatocele, dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome, cryptorchidism, diphallia, postorgasmic illness syndrome, penoscrotal transposition, congenital bilateral absence of vas deferens, posterior hypospadias, isolated micropenis, male reproductive system neoplasm, fournier gangrene, congenital agenesis of the scrotum, scrotal disorder, congenital megaprepuce, epididymis disease
Subtypes (5): prostatic cyst, prostate calculus, prostatitis, benign prostatic hyperplasia, prostate neoplasm
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Dalfampridine.
Clinical trials & evidence
Clinical trials
Clinical trials: 32.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 21 |
| PHASE1/PHASE2 | 3 |
| PHASE2 | 3 |
| PHASE1 | 3 |
| PHASE4 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05803096 | PHASE4 | COMPLETED | Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain |
| NCT06684626 | PHASE3 | COMPLETED | The Role of Butirprost® in Combination With Antibiotics in Chronic Bacterial Prostatitis (CBP) Treatment |
| NCT03543189 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy |
| NCT06190899 | PHASE1/PHASE2 | RECRUITING | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer |
| NCT00037141 | PHASE1/PHASE2 | COMPLETED | Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) |
| NCT03658408 | PHASE2 | WITHDRAWN | 4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy |
| NCT04461509 | PHASE2 | COMPLETED | High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy |
| NCT05150236 | PHASE2 | UNKNOWN | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC |
| NCT01307852 | PHASE1 | COMPLETED | In Vivo Dosimetry During Prostate Cancer Radiotherapy |
| NCT04249947 | PHASE1 | TERMINATED | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) |
| NCT04760483 | PHASE1 | UNKNOWN | Office Based Transperineal Laser Ablation for Benign Prostatic Hyperplasia HYPERPLASIA |
| NCT04288427 | Not specified | RECRUITING | 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy |
| NCT05470127 | Not specified | RECRUITING | Evaluation of the Performance of a Novel Prostate Biopsy System Compared With Standard of Care Biopsy Needle on Quantitative and Qualitative Tissue Parameters |
| NCT05682742 | Not specified | ACTIVE_NOT_RECRUITING | Clinical Investigation of the da Vinci Surgical System |
| NCT06636747 | Not specified | RECRUITING | High Resolution Diffusion Weighted Imaging in Prostate |
| NCT06944743 | Not specified | RECRUITING | TURP Inpatient With Underactive Bladder With BOO |
| NCT07130708 | Not specified | RECRUITING | Exploring the Potential of Robotic Telesurgery in Remote Settings |
| NCT00210249 | Not specified | COMPLETED | Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment |
| NCT00756561 | Not specified | COMPLETED | HOP-2A - Intratesticular Hormone Levels |
| NCT03503643 | Not specified | COMPLETED | Hemi-Gland Cryoablation for Prostate Cancer at UCLA |
| NCT03589196 | Not specified | UNKNOWN | Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate: A RCT |
| NCT03597386 | Not specified | WITHDRAWN | ConfirmMDx Assay in Multiparametric MRI (mpMRI) PIRADS Scored Lesions After a Negative MR/US Fusion Biopsy |
| NCT03847753 | Not specified | COMPLETED | Exploring the Comorbidity Between Mental Disorders and General Medical Conditions |
| NCT04026763 | Not specified | UNKNOWN | MR/TRUS Fusion Guided Prostate Biopsy |
| NCT04462926 | Not specified | UNKNOWN | Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed |
| NCT04599218 | Not specified | UNKNOWN | MR/TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer |
| NCT04656678 | Not specified | UNKNOWN | Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Intermediate Risk Prostate Cancer |
| NCT04699552 | Not specified | WITHDRAWN | Effect of Laser Settings on Postoperative Voiding Symptoms in Patients Undergoing Holmium Laser Enucleation of the Prostate |
| NCT04831307 | Not specified | UNKNOWN | 68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical |
| NCT05399940 | Not specified | COMPLETED | The Relationship Between Serum PSA Levels and WBC, Delta Neutrophil Index (DNI) and Other Hematological Parameters |
| NCT05834270 | Not specified | COMPLETED | Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH |
| NCT05902637 | Not specified | COMPLETED | The Efficacy of Mapping for Cognitive Prostate Biopsy |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ALCOHOL | 4 | 1 |
| DALFAMPRIDINE | 4 | 1 |
| DAROLUTAMIDE | 4 | 1 |
| FINASTERIDE | 4 | 1 |
| HYALURONATE SODIUM | 4 | 1 |
| LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN | 4 | 1 |
| OXYGEN | 4 | 1 |
| GEDATOLISIB | 3 | 1 |
| GOZETOTIDE ALF-18 | 3 | 1 |
| RIMIDUCID | 2 | 1 |
| CHEMBL4457117 | 0 | 1 |
| CHEMBL5206636 | 0 | 1 |
| CHEMBL4777013 | 0 | 1 |